Compare Abeona Therapeutics Inc (ABEO) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs MobilEye Global Inc — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while MobilEye Global Inc trades at $8.96 (market cap $8.00B). The key difference: MobilEye Global Inc is far larger — about 21.4× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | MBLY | |
|---|---|---|
Market Cap | $373.32M | $8.00B |
Sector | Health | Technology |
52-Week High | $7.23 | $18.64 |
52-Week Low | $4.17 | $6.56 |
Enterprise Value | $228.22M | $6.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Mobileye (MBLY) trades at $10.00, up 4.49% today, with a bullish technical signal from moving averages and strong analyst support. The stock shows negative profitability with a net income margin of -203.97% in 2026 but maintains solid revenue growth, reaching $2.0B. Recent news highlights its strategic shift to launch a vertically integrated U.S. robotaxi service in 2027, positioning it against competitors like Waymo and Tesla.
The outlook is cautiously optimistic due to the robotaxi initiative's potential, but high execution risks and persistent losses pose challenges. Analysts project a consensus price target of $10.36, with 57.69% recommending Buy. Investors should weigh the growth opportunity against the company's current unprofitability and competitive pressures in the autonomous vehicle sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
